FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:402-404 August 6, 1998 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Wright, J. C. PubMed Citation

Patients, providers, payers, politicians, and the public are keenly interested in evaluating the worthiness of diverse health care interventions. Sometimes the attention is focused on existing interventions (such as childhood immunizations); at other times the attention is on potential interventions (such as an AIDS vaccine). The evaluations are often problematic because the magnitude of changes in health outcomes is difficult to interpret. And most health care and safety interventions yield only small changes in the health of populations despite causing dramatic changes in the health of some patients.

Researchers often assess health outcomes by counting adverse events (e.g., deaths and . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Palmer, A. J., Tucker, D. M. D., Valentine, W. J., Roze, S., Gabriel, S., Cordonnier, D. J. (2005). Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant 20: 1103-1109 [Abstract] [Full Text]  
• Palmer, A. J., Annemans, L., Roze, S., Lamotte, M., Rodby, R. A., Cordonnier, D. J. (2003). An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant 18: 2059-2066 [Abstract] [Full Text]  
• van den Akker-van Marle, M. E., van Ballegooijen, M., van Oortmarssen, G. J., Boer, R., Habbema, J. D. F. (2002). Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies. JNCI J Natl Cancer Inst 94: 193-204 [Abstract] [Full Text]  
• Redelmeier, D. A, Singh, S. M (2001). Longevity of screenwriters who win an academy award: longitudinal study. BMJ 323: 1491-1496 [Abstract] [Full Text]  
• Redelmeier, D. A., Lustig, A. J. (2001). Prognostic Indices in Clinical Practice. JAMA 285: 3024-3025 [Full Text]  
• Redelmeier, D. A., Singh, S. M. (2001). Survival in Academy Award-Winning Actors and Actresses. ANN INTERN MED 134: 955-962 [Abstract] [Full Text]  
• Hayden, G. F (1999). Alliteration in medicine: a puzzling profusion of p's. BMJ 319: 1605-1608 [Abstract] [Full Text]